Document is current
Any future updates will be listed below
-
Authors
Fernandez, Brianna
Passanisi, Victor J.
Ashraf, Humza M.
Spencer, Sabrina L. https://orcid.org/0000-0002-5798-3007
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1DP2CA238330-01)
U.S. Department of Health & Human Services | National Institutes of Health (R01 R01AG082942)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31 CA284877)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM142607)
- License Information
-
More Information
Article History
Received: 15 February 2025
Accepted: 14 November 2025
First Online: 23 December 2025
Competing interests
: S.L.S. has a sponsored research agreement with Genesis Therapeutics, had a past sponsored research agreement with Pfizer Inc., is on the scientific advisory board of Meliora Therapeutics, has been a paid consultant for Astex Therapeutics and Guidepoint Global, and has received honoraria/speaking fees from Blueprint Therapeutics, Ensem Therapeutics, Genentech Inc, Iambic Therapeutics, Nereid Therapeutics, Odyssey Therapeutics, and Pfizer Inc. A joint patent has been filed by the Regents of the University of Colorado and Pfizer Inc. related to CDK2 inhibitors (PCT/IB2021/052894). The remaining authors declare no competing interests.
